Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report

• Published in: Oncology letters Vol. 12; no. 1; pp. 213 - 216
• Main Authors: CHUNG, SANG MI, CHOI, SEONG JI, KIM, MIN JUNG, CHOI, JUNG YOON, KIM, HONG JUN, LEE, SUK-YOUNG, KANG, EUN JOO
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.07.2016; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Antigens; Asbestos; Cancer; Case reports; Chemotherapy; Cisplatin; Drug dosages; Drug therapy; Dyspnea; Gastric cancer; Hematology; Hospitals; Lung cancer; Lymphatic system; malignant mesothelioma; Medical imaging; Medical prognosis; Mesothelioma; Metastasis; Methods; NMR; Nuclear magnetic resonance; Oncology; Patient outcomes; Patients; Pemetrexed; pericardium; Peripheral neuropathy; Radiation therapy; Thoracic tumors; Tomography; Tumors; pemetrexed; pericardium; cisplatin; malignant mesothelioma; chemotherapy
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2016.4598

Primary malignant pericardial mesothelioma (PMPM) is a rare tumor with poor prognosis. Surgery is the treatment of choice, but numerous cases are inoperable. For the treatment of inoperable or metastatic cases, systemic chemotherapy is required. However, a standard chemotherapeutic regimen for the treatment of pericardial mesothelioma has not yet been established. Chemotherapy involving pemetrexed and cisplatin has been actively used in the treatment of pleural or peritoneal mesothelioma, and may be considered for the treatment of PMPM. The present study reports the case of a patient with PMPM with lung metastasis who demonstrated a positive response to treatment with pemetrexed and cisplatin followed by pemetrexed maintenance chemotherapy, leading to prolonged progression-free survival for 21 months.